Findings from a meta-analysis presented at the virtual 56th EASD Annual Meeting suggest that patients with rheumatoid arthritis have a significantly elevated risk for developing diabetes.
Machine learning models based on gene expression and DNA methylation profiles may accurately predict response to adalimumab and etanercept in patients with rheumatoid arthritis, research from the Netherlands shows.
The majority of patients with systemic or polyarticular-course juvenile idiopathic arthritis do not develop radiographic joint progression during the first 2 years of tocilizumab treatment, research shows.
Among patients with rheumatoid arthritis receiving stable DMARD treatment, long-term glucocorticoid use is associated with a dose-dependent increase in the risk for serious infection, with a “small but significant” risk even at the lowest doses, researchers report.
Treatment with the IL-6 receptor inhibitor sarilumab is associated with a greater improvement in glycemic control than conventional DMARDs or adalimumab among patients with comorbid rheumatoid arthritis and diabetes, indicate findings from a post-hoc analysis.
Patients with early rheumatoid arthritis who report higher HAQ-measured disability after taking DMARDs for a year are at greater risk for all-cause mortality than those who report lower disability scores, indicate findings from the Canadian Early Arthritis Cohort.
Tocilizumab does not significantly improve skin fibrosis in patients with diffuse cutaneous systemic sclerosis but may preserve lung function among individuals with early interstitial lung disease, say researchers.
Individuals with treatment-naïve early rheumatoid arthritis show evidence of cardiovascular disease that improves following initiation of DMARD therapy, UK research shows.
The authors of a systematic review report that DMARD treatment does not seem to have a detrimental impact on fertility in patients with rheumatoid arthritis, but limited evidence means that more research is needed.
Fatigue among patients with early rheumatoid arthritis improves significantly following the initiation of DMARDs, but maximal improvements may not occur until 6 months after remission, research shows.
The type I interferon inhibitor JNJ-55920839 is well tolerated and has demonstrated preliminary efficacy against systemic lupus erythematosus in a phase 1 trial, researchers report.
Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.
Anti-carbamylated vimentin antibodies may be associated with treatment response and structural damage progression among patients with rheumatoid arthritis, shows a post-hoc analysis of data from the phase 3 RA-BEGIN trial.
Patients with rheumatic and musculoskeletal diseases are almost twice as likely to adhere to COVID-19 social distancing regulations as the general population, suggests research conducted in the Netherlands.
Treatment with biologic DMARDs does not elevate the risk for lymphoma among patients with rheumatoid arthritis, report researchers from the ARTIS study group.
A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.
Women are less likely than men to hold senior academic rheumatology positions and are under-represented as senior authors of published research articles, suggest findings from two studies published in Arthritis & Rheumatology.
Treatment with the IL-6 receptor inhibitor tocilizumab may be associated with a reduction in time on mechanical ventilation, shorter hospital stay, and decreased mortality risk among patients with severe COVID-19, suggest findings from three studies.